Navigation Links
Abbott Advances Its Revolutionary Fully Bioabsorbable Drug Eluting Stent With Initiation of Next Phase of Clinical Trial
Date:3/24/2009

mitted to continuing to invest in this promising technology and to bring it to market as soon as possible."

The ABSORB trial reinforces Abbott's commitment to research and develop innovative devices in vascular care. Abbott's robust vascular research program includes clinical trials in peripheral artery disease, carotid artery disease, and coronary artery disease. Key products in the vascular pipeline include: the Omnilink Elite(TM) Peripheral Stent System; the EMBOSHIELD NAV6(TM) Embolic Protection System for carotid stenting; and the XIENCE PRIME(TM) Everolimus Eluting Coronary Stent System, which builds upon the proven performance of Abbott's market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System.

Onmilink Elite, EMBOSHIELD NAV6 and XIENCE PRIME are investigational devices and are not available for sale.

About the ABSORB Clinical Trial

The ABSORB trial is a prospective, non-randomized (open label), two-phase study designed to enroll approximately 110 patients in Australia, Belgium, Denmark, France, the Netherlands, New Zealand, Poland and Switzerland. Key endpoints of the study include assessments of safety - MACE and stent thrombosis rates - at 30 days; six, nine, 12 and 18 months; and two years, with additional annual clinical follow-up for up to five years, as well as an assessment of the acute performance of the bioabsorbable drug eluting stent, including successful deployment of the system. Other key endpoints of the study include imaging assessments by angiography, intravascular ultrasound (IVUS), optical coherence tomography (OCT), and other state-of-the-art invasive and non-invasive imaging modalities at six months, one year and two years.

Abbott's bioabsorbable drug eluting device delivers everolimus, a drug that inhibits tissue proliferation. The device props open and supports a narrowed blood vessel until the vessel heals, restoring blood flow, and is abs
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. The Lancet Publishes Two-Year Results of Abbotts Fully Bioabsorbable Drug Eluting Stent
2. Abbott and Enanta Initiate Phase 1 Clinical Trial on ABT-450 HCV Protease Inhibitor
3. Abbott Receives Complete Response Letter From FDA for Controlled-Release Hydrocodone With Acetaminophen
4. Abbotts XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
5. Continuous Treatment With Abbotts HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment
6. Abbotts Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines
7. Abbotts Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes
8. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
9. Abbott Presents Long-Term Data From Extension Study Showing Adult Crohns Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission
10. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
11. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... 22, 2014 Research ... addition of the  "Global Operating Room Equipment ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,An operating ... environment in a healthcare facility used to ... technically advanced equipment, which ensures patient care ...
(Date:8/22/2014)... /CNW/ - On Aug. 20, at its annual meeting ... Association (CMA) voted on and approved a delegate resolution ... cannabis. Bedrocan Cannabis Corp., a leading Canadian licensed producer ... The CMA is quite right to point ... any plant material, including medicinal cannabis. While some patients, ...
(Date:8/22/2014)... , Aug. 22, 2014 Research and ... "Global and Chinese Intravenous Catheter Industry Report 2014" ... and Chinese Intravenous Catheter Industry Report 2014 is a ... the global intravenous catheter industry with a focus on ... overview of the industry including definitions, classifications, applications and ...
Breaking Medicine Technology:Global Operating Room Equipment Market 2014-2018: Key Vendors are Getinge, STERIS, Stykron and TRUMPF Medical Systems 2Bedrocan Canada Statement Regarding Canadian Medical Association Motion on Smoking Marijuana 2Global and Chinese Intravenous Catheter Industry Report 2014 2
... 2, 2012 CVS Caremark Corporation (NYSE: CVS ) ... months ended March 31, 2012. (Logo: http://photos.prnewswire.com/prnh/20090226/NE75914LOGO ... , Net revenues increased 19.9% to a record $30.8 ... , Retail Pharmacy segment same stores sales increased ...
... Ill., May 2, 2012  Celebrity chef Spike Mendelsohn knows all ... – especially for a person with acid reflux disease (ARD). ... Spike has also had to learn how to turn down ... awareness and understanding about the importance of managing heartburn symptoms ...
Cached Medicine Technology:CVS Caremark Reports Record First Quarter Results 2CVS Caremark Reports Record First Quarter Results 3CVS Caremark Reports Record First Quarter Results 4CVS Caremark Reports Record First Quarter Results 5CVS Caremark Reports Record First Quarter Results 6CVS Caremark Reports Record First Quarter Results 7CVS Caremark Reports Record First Quarter Results 8CVS Caremark Reports Record First Quarter Results 9CVS Caremark Reports Record First Quarter Results 10CVS Caremark Reports Record First Quarter Results 11CVS Caremark Reports Record First Quarter Results 12CVS Caremark Reports Record First Quarter Results 13CVS Caremark Reports Record First Quarter Results 14CVS Caremark Reports Record First Quarter Results 15CVS Caremark Reports Record First Quarter Results 16Chef Spike Mendelsohn Dishes on How to Turn Down the Heat on Acid Reflux Disease 2Chef Spike Mendelsohn Dishes on How to Turn Down the Heat on Acid Reflux Disease 3Chef Spike Mendelsohn Dishes on How to Turn Down the Heat on Acid Reflux Disease 4Chef Spike Mendelsohn Dishes on How to Turn Down the Heat on Acid Reflux Disease 5
(Date:8/23/2014)... 2014 GranuFlo lawsuit ( http://www.thegranuflolawsuit.com ... NaturaLyte dialysis concentrate recall continue to mount in ... Court, District of Massachusetts, Bernstein Liebhard LLP reports. ... the U.S. Judicial Panel on Multidistrict Litigation (JPML) ... pending in the proceeding. In July, the Panel ...
(Date:8/23/2014)... August 23, 2014 "When men sit ... into contact with the dirty water inside the bowl, ... itself," said one of two inventors from Naugatuck, and ... we developed this protective device." , They developed the ... surfaces, including the water, bowl and seat. This minimizes ...
(Date:8/23/2014)... August 23, 2014 On Monday, August ... a data breach suffered by Community Health Systems, ... compromise of 4.5 million records containing Personally Identifiable Information ... According to Mandiant, who was engaged to investigate the ... an advanced group of cyber attackers based in China, ...
(Date:8/23/2014)... Pixel Film Studios, a leader of Final Cut Pro ... Vol.3, a customizable title tool for FCPX , ... dragging ProIntro Vol.3 in their timeline" says Christina Austin, CEO ... saver and i think our users will agree" , ProIntro ... made with Final Cut Pro X users in mind. Achieve ...
(Date:8/23/2014)... Wilmington, NC (PRWEB) August 23, 2014 ... across North Carolina. It’s no different in Wilmington, NC. ... Young adults are falling victim to drug and alcohol ... young people are looking to overcome substance abuse, but ... Finding an adolescent treatment facility can be a challenge ...
Breaking Medicine News(10 mins):Health News:GranuFlo Lawsuits Mount in Federal Litigation, as Filings Surpass 2,000, Bernstein Liebhard LLP Reports 2Health News:GranuFlo Lawsuits Mount in Federal Litigation, as Filings Surpass 2,000, Bernstein Liebhard LLP Reports 3Health News:GranuFlo Lawsuits Mount in Federal Litigation, as Filings Surpass 2,000, Bernstein Liebhard LLP Reports 4Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 2Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 3Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 4Health News:A new plugin was announced today, ProIntro Vol.3 from Pixel Film Studios for Final Cut Pro X 2Health News:Troubled Teens Wilmington Helpline Guides Adolescents to the Path of Recovery 2
... Medicine physicians are currently utilizing a new treatment option ... full dose of radiation therapy during breast conserving surgery. ... first have surgery then undergo approximately six weeks of ... have busy schedules or do not have access to ...
... human papillomavirus (HPV) vaccine doses over a longer period of ... levels that were comparable to the standard vaccine schedule, according ... JAMA , a theme issue on infectious disease and immunology. ... presented the findings of the study at a JAMA ...
... 769 men from across the United States recently diagnosed with ... the tumor or radiation poses no added risk of death. ... as the cancer,s progression and tumor growth are closely monitored ... the disease over time. None of the men, mostly ...
... created by the incomplete combustion of fossil fuels and ... their children, according to a new study. Researchers found ... birth, those children with high levels of a pollution ... of attention problems and anxiety/depression at ages 5 and ...
... For the first time in a human model, scientists have ... researchers can now develop better and more efficient drugs to ... new brain cells, however, until now it was not known ... published in the journal Molecular Psychiatry , researchers from ...
... , MONDAY, April 11 (HealthDay News) -- Progressive resistance training ... function better in daily life, researchers say. A team ... of available evidence and concluded that an adult can add ... increase their overall strength by 25 percent to 30 percent ...
Cached Medicine News:Health News:Radiation at time of lumpectomy may offer faster, more precise treatment for breast cancer patients 2Health News:Radiation at time of lumpectomy may offer faster, more precise treatment for breast cancer patients 3Health News:Lengthening dosing schedule of HPV vaccine may provide effective option for expanding use of vaccine 2Health News:Lengthening dosing schedule of HPV vaccine may provide effective option for expanding use of vaccine 3Health News:Closely monitoring low-risk prostate cancer, with biopsy, does not raise risk of death 2Health News:Closely monitoring low-risk prostate cancer, with biopsy, does not raise risk of death 3Health News:Prenatal exposure to certain pollutants linked to behavioral problems in young children 2Health News:New target for developing effective anti-depressants 2Health News:Progressive Weight Training Can Boost Seniors' Strength 2
Used for drainage and retrograde pyelogram. The spiral tip aids in negotiation of a tortuous or partially obstructed ureter. Supplied sterile in peel-open packages. Intended for one-time use....
Used for drainage and retrograde pyelogram. Supplied sterile in peel-open packages. Intended for one-time use....
Used for drainage and navigation of a tortuous ureter. The tapered tip eases placement as there are no edges to interfere with the ureteral orifice. Supplied sterile in peel-open packages. Intended f...
These flexible stone retrieval devices are reusable, 3 Fr in diameter, with a working length of either 60 cm or 115 cm...
Medicine Products: